No Data
Eupraxia Surges 15% in U.S. Pre-market Trading After Reporting Positive Data From Resolve Phase 1b/2a Trial
Press Release: Eupraxia Pharmaceuticals Announces CFO Succession
Eupraxia Pharmaceuticals Up 5.5% In US Premarket As Says DiffuSphere Technology Demonstrates Targeted Drug Release
Eupraxia's DiffuSphere Technology Demonstrates Targeted Drug Release While Minimizing Systemic Exposure for a Period of More Than Six Months
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
